Skip to main content

Table 1 Background characteristics of patients

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Patients

40

Age, median [range]

67 [33–78]

Sex, male (%)

15 (37.5)

BW (kg), median [range]

58.0 [35.3–97.1]

Histopathology, follicular (%)

15 (37.5)

Performance status, ≥ 1

17 (42.5)

Sum of tumor diameters (mm), median [range]

82 [11–169]

Tumor related symptoms at baseline, yes (%)

24 (60)

Thyroglobulin doubling time, year

0.7 (0.12–3.0)

Treatment period (months), median [range]

29.5 [6.8–61.5]

Observation period (months), median [range]

32.5 [7.4–61.5]

Dose Intensity, median [range]

9.6 [4.0–16.4]

Best response in RECIST criteria, PR (%)

29 (72.5)

eGFR at baseline (mL/min/1.73 m2), median [range]

72.2 (43.6–119.1)

Proteinuria grade 1 at baseline, yes (%)

2 (5)

Past hypertension history (%)

24 (60)

Past diabetes mellitus history (%)

3 (7.5)

Past renal history (%)

6 (15)

Renal metastasis, baseline (%)

3 (7.5)

latest (%)

3 (7.5)

Liver metastasis, baseline (%)

5 (12.5)

latest (%)

7 (17.5)

Proteinuria grade 3, yes (%)

21 (52.5)

Treatment continuation, yes (%)

20 (50)

Treatment termination due to renal problem, yes (%)

7 (17.5)